Table 4 Treatment response evaluations in patients who received chemotherapy plus trastuzumab
Group (A) | first-line | second-line | third-line | four-line |
|---|---|---|---|---|
Number of cases | N = 3 | N = 16 | N = 9 | N = 5 |
CR | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
PR | 1 (51.6%) | 4 (25.0%) | 0 (0.0%) | 0 (0.0%) |
SD | 2 (42.2%) | 10 (62.5%) | 6 (66.7%) | 2 (40.0%) |
PD | 0 (0.0%) | 2 (12.5%) | 3 (33.3%) | 3 (60.0%) |
ORR | 1 (51.6%) | 4 (25.0%) | 0 (0.0%) | 0 (0.0%) |
DCR | 3 (93.8%) | 14 (87.5%) | 6 (66.7%) | 2 (40.0%) |